Biphasic multicomponent pharmaceutical dosage forms containing substances able to modify the partitioning of drugs

• US 6,495,160 B2
• Filed: 10/01/1999
• Issued: 12/17/2002
• Est. Priority Date: 05/13/1997
• Status: Expired due to Fees

• Current Assignee: Eurand International S.p.A. (Abbvie Incorporated)
• Original Assignee: Eurand International S.p.A. (Abbvie Incorporated)
• Inventors: Del Curto, Maria Dorly, Coceani, Nicoletta, Esposito, Pierandrea, Carli, Fabio
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): TRAN, SUSAN T
• Application Number:
  US09/214,813
• Publication Number:
  US 20020034539A1
• Time in Patent Office: 1,173 Days
• Field of Search: 424/443, 424/449, 424/450, 424/451, 424/455, 424/456, 424/458
• US Class Current: 424/451
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00

Abstract

The invention provides a biphasic multicomponent pharmaceutical composition consisting of an oil phase and a water phase, comprising one or more lipophilic or oil carrier, one or more hydrophilic or aqueous carrier, one or more ionic or nonionic type surfactant, one or more cosurfactant, one or more active principle for pharmaceutical use, and a compound able to modify the partition of the active principle between said phases selected from the group consisting of N- methyl pyrrolidone (NMP), isopropyl alcohol, propylene glycol, ethoxy-di-glycol, β-cyclodextrin, hydroxypropyl β-cyclodextrin and dimethyl β-cyclodextrin. The invention also provides a method for making the composition.

Claims

1. A process for the preparation of a biphasic multicomponent pharmaceutical composition consisting of an oil phase and a water phase wherein the composition comprises:

one or more lipophilic or oil carrier;

one or more hydrophilic or aqueous carrier;

one or more ionic or nonionic surfactant;

one or more cosurfactant; and

one or more active principle for pharmaceutical use, wherein said composition further comprises a compound able to modify the partition of the active principle between said phases, selected from the group consisting of N-methyl pyrrolidone (NMP), β

-cyclodextrin, hydroxypropyl β

-cyclodextrin and dimethyl β

-cyclodextrin, the preparation process comprising the following steps;

a) maintaining a mixture consisting of the lipophilic or oil carrier, the cosurfactant and a fraction of the surfactant under mild stirring and temperature control;

b) adding the hydrophilic or aqueous carrier to the mixture of step a) while maintaining the mild stirring and the temperature control;

c) adding the compound able to modify the partition of the active principle to one of the two phases before the mixing, according to its miscibility with the aqueous or oil phase;

d) adding the residual fraction of surfactant;

e) adding the active principle, in dissolved and/or dispersed form, to the composition already constituted.

2. The process according to claim 1 wherein the temperature of steps a) and b) is between 5 and 85°

C.

3. The composition according to claim 1 wherein the composition is further formulated into systems for transdermal use in form of matrix systems, reservoir systems, multilayer systems and drug- in-adhesive systems.

4. The composition according to claim 1 wherein the composition is further formulated in systems for oral or transmucosal use in form of liquid capsules, soft-gel capsules, suppositories and applicators.

5. A process for the preparation of a biphasic multicomponent pharmaceutical composition consisting of an oil phase and a water phase, comprising:

one or more lipophilic or oil carrier having a wet percentage of between 0.5 to 80%;

one or more hydrophilic or aqueous carrier having a weight percentage of between 0.5 to 70%;

one or more ionic or nonionic surfactant having a weight percentage of between 0.1 to 50%;

one or more cosurfactant having a weight percentage of between 0 and 50%; and

one or more active principle for pharmaceutical use having a weight percentage of between 0.1 to 60%, wherein said composition further comprises a compound able to modify the partition of the active principle between said phase having a weight percentage of between 0.1 to 30%, selected from the group consisting of N-methyl pyrrolidone (NMP), β

-cyclodextrin, hydroxypropyl β

-cyclodextrin and dimethyl β

-cyclodextrin, comprising the following steps;

a) maintaining a mixture consisting of the lipophilic or oil carrier, the cosurfactant and a fraction of the surfactant under mild stirring and temperature control;

b) adding the hydrophilic or aqueous carrier to the mixture of step a) while maintaining the mild stirring and the temperature control;

c) adding the compound able to modify the partition of the active principle to one of the two phases before the mixing, according to its miscibility with the aqueous or oil phase;

d) adding the residual fraction of surfactant;

e) adding the active principle, in dissolved and/or dispersed form, to the composition already constituted.

6. The process according to claim 5 wherein the temperature of steps a) and b) is between 5 and 85°

C.

7. The process according to claim 5 wherein the composition is further formulated into systems for transdermal use in form of matrix systems, reservoir systems, multilayer systems and drug- in-adhesive systems.

8. The process according to claim 5 wherein the composition is further formulated in systems for oral or transmucosal use in form of liquid capsules, soft-gel capsules, suppositories and appllicators.